Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
4086465 Canada, Inc. d/b/a International Protection Center and Consumers Protection Center, et al.
Penn National Gaming, Inc., In the Matter of
Penn National Gaming, Inc. agreed to sell a casino in Baton Rouge, Louisiana to settle charges that its acquisition of Argosy Gaming Company would create a monopoly for casino services in that area. Penn National agreed to sell Argosy's casino to Columbia Sussex Corporation within four months of the order becoming final.
3rd Union Card Services Inc., et al.
Service Brokers Associates, Inc., and Daniel Gonzalez, FTC
FGH International Corporation, Inti California, Inc., et al.
Sun Spectrum Communications Organization, Inc., et al.
NBTY, Inc. (formerly known as Nature's Bounty, Inc.), U.S. (for the FTC)
Sacane, Scott R., U.S. (for the FTC)
The complaint alleged that Scott R. Sacane, a Connecticut hedge fund manager, failed to comply with notification and waiting period requirements before making acquisitions of two companies through an investment fund that he controlled. Sacane eventually held more than 50 percent of the voting securities of Aksys Ltd. and more than $100 million of voting securities of Esperion Therapeutics, Inc., without complying with the HSR Act. Under the terms of a consent decree filed simultaneously with the suit, Sacane agreed to pay a civil penalty of $350,000 to settle the charges.
BJ's Wholesale Club, Inc., In the Matter of
Novartis AG, In the Matter of (Eon Labs, Inc)
To resolve competitive concerns for three generic pharmaceuticals that arose from Novartis AG’s acquisition of Eon Labs, Inc., Novartis agreed to divest all the assets necessary to manufacture and market generic desipramine hydrochloride tablets, orphenadrine citrate extended release (ER) tablets, and rifampin oral capsules in the United States to Amide within 10 days of Novartis’s acquisition of Eon. Further, Novartis, through its Sandoz generic pharmaceuticals division, will supply Amide with orphenadrine citrate ER and desipramide hydrochloride tablets until Amide obtains FDA approval to manufacture the products itself, and will assist Amide in obtaining all necessary FDA approvals.